PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

• R. Fonseca,
• J. Kuroda,
• T. Ishida,
• R. Popat,
• J. S. Huang,
• A. Yver,
• E. Vandendries,
• M. Elmeliegy,
• W. D. Ma,
• D. W. Sborov

Affiliations

R. Fonseca

1 Division of Hematology/Oncology, Mayo Clinic Hospital, Phoenix, United States of America

J. Kuroda

2 Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto

T. Ishida

3 Japanese Red Cross Medical Center, Shibuya, Japan

R. Popat

4 NIHR UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, United Kingdom

J. S. Huang

5 Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan

A. Yver

6 Pfizer Inc, Paris, France

E. Vandendries

7 Pfizer Inc, Cambridge

M. Elmeliegy

8 Pfizer Inc, La Jolla

W. D. Ma

9 Pfizer Inc, New York

D. W. Sborov

10 Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, Salt Lake City, United States of America